Innate Pharma SA (IPHA) Price Prediction & ForecastIPHAInnate Pharma SA

Alphio's IPHA stock price prediction model matches the current Innate Pharma SA tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.43 (+2.35%). The 1-week path is $1.41 (+0.72%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Currently, Innate Pharma SA (IPHA) is not a strong buy. The stock is trading at $1.40, significantly below its 52-week high of $2.71, indicating a potential for recovery but also substantial risk. The RSI is at 30.25, suggesting it is oversold, which could indicate a buying opportunity if the fundamentals improve. However, the company reported a gross margin of -889.87% in Q1 2026, reflecting severe financial distress, and a net income loss of €27.6 million, which raises concerns about its sustainability. The main risk is the upcoming earnings report on November 5, 2026, which could further impact the stock's performance depending on the results.

Innate Pharma SA (IPHA) last closed at $1.4, losing -1.75%. These facts feed the 1-day and 1-week IPHA price prediction above.